Childhood Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
|
31823165 |
2020 |
Childhood Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter hypermethylation was detected in 38.7% of glioblastoma patients.
|
31701343 |
2020 |
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Histological examination confirmed a wild-type (WT) IDH1/2, MGMT (DNA repair enzyme O6-methylguanine-DNA methyltransferase) methylated glioblastoma with a proliferative index focally as high as 20%.
|
31173153 |
2020 |
Childhood Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In addition to its benefits for molecular subgrouping and copy number analysis of brain tumors, DNA-methylation based classification is a highly reliable tool for the assessment of MGMT promoter methylation status in glioblastoma patients.
|
31784096 |
2020 |
Childhood Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The CpG methylation status of the MGMT promoter strongly correlates with clinical outcome and, therefore, is used as prognostic marker during glioblastoma therapy.
|
31395346 |
2020 |
Childhood Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Although the two classical molecular markers of glioblastoma including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation are associated with overall survival rate of glioblastoma patients, they are not specific to the survival outliers.
|
31159876 |
2019 |
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Exploring this novel combined approach in the clinic to treat glioblastoma patients with MGMT promoter-unmethylated tumors is warranted.
|
30537486 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT) is a validated predictor of benefit from temozolomide (TMZ) in glioblastoma.
|
30579113 |
2019 |
Childhood Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We have assessed MGMT methylation status in blood and tissue samples from unresected glioblastoma patients who had been included in the randomized GENOM-009 trial.
|
31366977 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.
|
31058280 |
2019 |
Childhood Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Data from a previous unrandomised phase 2 trial suggested that lomustine-temozolomide plus radiotherapy might be superior to temozolomide chemoradiotherapy in newly diagnosed glioblastoma with methylation of the MGMT promoter.
|
30782343 |
2019 |
Childhood Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The purpose of this study was to determine the effect of disulfiram (DSF), an aldehyde dehydrogenase inhibitor, on in vitro radiosensitivity of glioblastoma cells with different methylation status of O6-methylguanine-DNA methyltransferase (MGMT) promoter and the underlying mechanism of such effect.
|
30121967 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition.
|
30549269 |
2019 |
Childhood Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
|
31208813 |
2019 |
Childhood Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Surprisingly, integrative analyses demonstrated that O6-methylguanine-DNA methyltransferase methylation and isocitrate dehydrogenase mutation status were equally distributed among glioblastoma metabolic profiles.
|
30476237 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier.
|
30399573 |
2019 |
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Instead, a difference in survival outcomes was confirmed in unmethylated-MGMT GB patients with better survival for patients undergoing to SDRT, particularly in sub-total resection.
|
31325903 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Temozolomide (TMZ) is still a first-line treatment, but resistance is inevitable even in MGMT-deficient glioblastoma cells.
|
31833081 |
2019 |
Childhood Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The absence of systematic and clinically relevant changes in HRQOL and neurocognitive function combined with the survival benefit of lomustine-temozolomide versus temozolomide alone suggests that a long-term net clinical benefit exists for patients with newly diagnosed glioblastoma with methylation of the MGMT promoter and supports the use of lomustine-temozolomide as a treatment option for these patients.
|
31488360 |
2019 |
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Methylation of the O(6)-Methylguanine-DNA methyltransferase (MGMT) promoter is predictive for treatment response in glioblastoma patients.
|
31167648 |
2019 |
Childhood Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ).
|
31325144 |
2019 |
Childhood Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We showed that ionizing radiation and temozolomide reduced the viability of cancer stem cells from GBM patients, as well as modified MGMT gene and miRNA-181d expression in cancer stem cells, suggesting that miRNA-181d interferes in the glioblastoma cancer stem cell response to treatment with temozolomide and ionizing radiation.
|
31226325 |
2019 |
Childhood Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epigallocatechin Gallate Preferentially Inhibits O<sup>6</sup>-Methylguanine DNA-Methyltransferase Expression in Glioblastoma Cells Rather than in Nontumor Glial Cells.
|
30558449 |
2019 |
Childhood Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical data (age, sex, extent of surgical resection), O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and pre-operative T2WI of 113 pathologically confirmed glioblastoma patients (from our institution, n = 61; from the Cancer Imaging Archive, n = 52) were retrospectively reviewed.
|
31150499 |
2019 |
Childhood Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This was not the case in glioblastoma cells expressing the repair protein MGMT, suggesting that the primary DNA lesion responsible for triggering HIPK2-mediated apoptosis is <i>O<sup>6</sup></i> -methylguanine.
|
30796178 |
2019 |